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This increase in cardiac imaging has occurred as the incidence
of coronary disease has remained stable, if not decreased
slightly (2,3). Cardiac stress testing and diagnostic angiog-
raphy are among the most commonly performed diagnostic
tests and are often used after revascularization, particularly
percutaneous coronary intervention (PCI).See page 447Previous studies have demonstrated signiﬁcant regional
variation in cardiac imaging and cardiac catheterization use
(4–7) that does not appear to be due entirely to differences in
patient characteristics. Cross-sectional and observational
studies examining variation in testing have demonstrated
that greater diagnostic testing results in increased invasive
procedures and interventions (8,9). Nevertheless, it is
unclear if these patterns represent increased use or overuse
from routine surveillance testing (5). Together, these
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440concerns prompted the American
College of Cardiology Foun-
dation to develop appropriate use
criteria for imaging stress testing
in the hope of decreasing varia-
tion and to target scenarios
providing the most clinical
beneﬁt (10,11).
Prior studies have not exam-
ined the institutional variations in
testing or the associated clinical
outcomes after PCI. To addressthese gaps, we assessed the relationship between rates of
diagnostic testing for coronary artery disease after PCI and
the incidence of repeat revascularization, acute myocardial
infarction (AMI), and death in a national patient cohort.
Methods
The Duke University Medical Center Institutional Review
Board granted a waiver of the requirement for informed
consent and authorization for this study, and the Duke
Clinical Research Institute conducted all analyses.
Data sources. The study population included all patients
undergoing PCI with stenting who were at least 65 years of
age, were admitted and discharged between January 2004
and December 2008, and were enrolled in the National
Cardiovascular Data Registry CathPCI Registry. The
CathPCI Registry is a large, national, clinical registry of
patients undergoing cardiac catheterization or PCI. For
each patient, the ﬁrst PCI with stent procedure captured in
the CathPCI Registry was considered to be the index event
and was treated as the initial unit of analysis. There was
a total of 672,617 eligible index events, of which 67% were
linked to a single record in the Centers for Medicare and
Medicaid Services (CMS) inpatient claims data for
patients >65 years of age using an established probabilistic
matching method (12,13). Index PCI events were matched
to CMS claims data using 3 variables: sex, age, and date of
service for the PCI procedure. Matching to the CMS data
allowed the identiﬁcation of subsequent inpatient and
outpatient claims. The patient was treated as the unit of
analysis.
The linked cohort was restricted to patients receiving only
stent type (either bare-metal or drug-eluting stents), allowing
comparisons by stent type. Multiple revascularization pro-
cedures within a single encounter were considered a single
revascularization event. Patients were excluded if they did not
have both Part A (inpatient hospital) and Part B (physician
services and outpatient hospital) Medicare coverage during
their index admissions. Also, patients were excluded if they
did not have physician claims for their index interventions or
had primary payers besides Medicare (Fig. 1A).
Study population. Because Version 3 of the CathPCI
Registry data collection form was implemented nationwide
on January 1, 2005, we restricted our analysis to patientstreated on or after this date; similarly, because we had
follow-up data through December 31, 2008, only patients
treated before December 31, 2007, were included to ensure
minimal 1-year follow-up (Fig. 1B). Patients who did not
have fee-for-service Medicare coverage for the entire follow-
up period were censored once they ceased to have such
coverage.
A 60-day blackout period after PCI was deﬁned for each
patient because diagnostic tests during this early period may
be performed for cardiac rehabilitation, staging of proce-
dures, or functional capacity assessments. Patients were
excluded if they did not survive this blackout period or did
not retain both Part A and Part B Medicare coverage.
Additionally, patients undergoing stress positron emission
tomography, coronary computed tomographic angiography,
or stress magnetic resonance imaging after the 60-day
blackout period were excluded, because these studies were
rarely performed in this cohort. Finally, we limited the
sample to those hospitals that performed at least 50 PCI
procedures during analysis period to eliminate hospitals with
low procedural volumes.
Data deﬁnitions. The use of cardiac stress testing with and
without imaging after coronary stent implantation was as-
sessed by examining testing patterns after the initial revas-
cularization procedure overall and stratiﬁed by type of test,
which were identiﬁed by Current Procedural Terminology
codes (see the Online Appendix for codes). The types,
numbers, and dates of any cardiac testing or imaging pro-
cedures 60 days after the index coronary stent placement
were used to stratify patients on the basis of type of ﬁrst
diagnostic test after stenting. Stress electrocardiography and
imaging procedures performed within 1 day of each other
were considered a single stress event.
The numbers and dates of repeat catheterizations and
coronary revascularization procedures (e.g., PCI or coronary
artery bypass grafting [CABG]) after the ﬁrst diagnostic test
were identiﬁed using Current Procedural Terminology and
International Classiﬁcation of Diseases-Ninth Revision,
Clinical Modiﬁcation codes. Last, AMI was deﬁned accord-
ing to International Classiﬁcation of Diseases-Ninth Revi-
sion, Clinical Modiﬁcation coding (see the Online Appendix
for codes).
Statistical analysis. Patient and hospital baseline charac-
teristics of patients undergoing index revascularization stent
procedures were provided overall and by hospital quartiles of
cumulative incidence rate stress testing at 12 months after
PCI using descriptive statistics (number of observations,
mean, standard deviation, median, 25th and 75th percen-
tiles, minimum, and maximum) for numerical (or contin-
uous) variables and with frequencies and percents for
categorical variables. Bivariate tests of association were based
on either Pearson chi-square tests for categorical variables or
Kruskal-Wallis tests for continuous or ordinal variables.
Time to ﬁrst stress test occurring at least 60 days after the
index revascularization episode was calculated using cumu-
lative incidence functions that accounted for administrative
Figure 1 Population Description
Description of (A) the linked dataset population and (B) the study population. BMS ¼ bare-metal stent(s); CCTA ¼ coronary computed tomographic angiography; CMS ¼ Centers
for Medicare and Medicaid Services; DES ¼ drug-eluting stent(s); MRI ¼ magnetic resonance imaging; NCDR ¼ National Cardiovascular Data Registry; PCI ¼ percutaneous
coronary intervention; PET ¼ positron emission tomography; Pts ¼ patients.
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441censoring; death, AMI, and catheterization were considered
competing risks. Cumulative incidence rates at 12 months
were calculated separately for each institution. Institutions
were categorized on the basis of quartiles of cumulative
incidence of stress testing. To examine trends of institutional
cumulative incidence rates at 12 months over calendar time,
we estimated an intraclass correlation from a linear random-
effects model with institution as a random effect.
Cause-speciﬁc Cox proportional hazards models were
used to estimate hazard ratios associated with risk for death
ﬁrst, AMI ﬁrst, and revascularization ﬁrst, with adjustment
for baseline variables that were selected a priori on the basis
of clinical expertise. A robust variance estimator was used to
account for the possible within-cluster correlation (14). We
adjusted for age, race, sex, body mass index, acute coronarysyndrome at the time of index PCI, peripheral vascular
disease, history of congestive heart failure, diabetes, hyper-
tension, dyslipidemia, current smoking status, cerebrovas-
cular disease, family history of coronary artery disease before
55 years of age, previous myocardial infarction more than
7 days before index PCI, chronic lung disease, drug-eluting
stent versus bare-metal stent, glomerular ﬁltration rate
<30 ml/min or receiving dialysis, previous PCI, previous
CABG, current congestive heart failure status, year of index
PCI, hospital type (government, private and teaching, or
private and nonteaching vs. university), mean annual PCI
volume, number of CMS-certiﬁed beds, and region. In each
model, patients were censored at the end of follow-up or at
365 or 720 days. To describe whether clinical events rates
(AMI, repeat revascularization, and death) differed by
Table 1
Baseline and Descriptive Characteristics at Time of Index Coronary Stenting by Quartiles of Site Cumulative Incidence
of Stress Test Use at 365 Days After Index PCI
Overall
(n ¼ 656 Hospitals)
Lowest Testing
Quartile 1
(n ¼ 164 Hospitals)
Quartile 2
(n ¼ 164 Hospitals)
Quartile 3
(n ¼ 164 Hospitals)
Highest Testing
Quartile 4
(n ¼ 164 Hospitals) p Value
Total patients 247,052 55,138 62,980 67,405 61,529
Age (yrs) 75 (74, 75) 75 (74, 75) 75 (74,75) 75 (74,76) 75 (74,76) 0.0119
75 44% 39% 44% 48% 45%
Men 57% 57% 57% 57% 58% 0.0584
Caucasian 93% (85%, 97%) 95% (90%, 98%) 92% (85%, 97%) 90% (82%, 96%) 93% (85%, 97%) <0.0001
BMI (kg/m2) 28 (28, 29) 29 (28, 29) 28 (28, 29) 27 (24, 31) 28 (28, 29) 0.0054
30 2% 3% 1% 0% 4%
Previous MI (>7 days) 25% 25% 25% 24% 24% 0.4666
Previous CHF, % 13% 13% 14% 12% 12% 0.0839
Family history of CAD, age <55
yrs
16% 16% 15% 18% 17% 0.9704
Hypertension 81% 81% 81% 82% 80% 0.4761
Diabetes 32% 32% 32% 32% 32% 0.4418
Renal failure 0.9999
30 ml/min  GFR <60 ml/min 37% 37% 37% 36% 37%
GFR 60 ml/min 59% 59% 59% 59% 59%
Cerebrovascular disease 15% 16% 15% 15% 15% 0.2880
Peripheral vascular
disease
14% 14% 14% 14% 14% 0.9597
Chronic lung disease 18% 19% 19% 17% 18% 0.0122
Dyslipidemia 74% 73% 74% 75% 74% 0.9252
Current smoker 12% 13% 13% 11% 11% <0.0001
Previous PCI 26% 25% 26% 27% 27% 0.1035
Previous CABG 21% 21% 22% 21% 21% 0.4203
ACS 62% 68% 63% 59% 58% <0.0001
CHF on presentation 11% 12% 12% 11% 10% 0.0174
DES used 79% 80% 80% 77% 79% 0.0569
No. of CMS-certiﬁed beds 362 (260, 511) 374 (252, 477) 387 (285, 536) 364 (263, 521) 339 (252, 490) 0.1939
Region <0.0001
Northeast 12% 7% 18% 12% 13%
Midwest 34% 46% 25% 34% 32%
South 33% 35% 40% 29% 27%
West 21% 12% 20% 24% 29%
Hospital proﬁt type 0.0021
Private, teaching site 37% 37% 40% 34% 37%
Private, nonteaching site 52% 46% 47% 56% 60%
Hospital type
Government 1% 3% 0.6% 0% 1% 0.0695
University 9% 13% 12% 10% 2% 0.0015
Annual PCI volume 594 (354, 907) 550 (329, 842) 601 (350, 928) 877 (556, 1,455) 564 (356, 832) 0.2221
Values are N, median (Q1, Q3), or %.
ACS ¼ acute coronary syndrome; BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CMS ¼ Centers for Medicare and
Medicaid Services; DES ¼ drug-eluting stent; GFR ¼ glomerular ﬁltration rate; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; Q ¼ quartile.
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442quartile of testing, we calculated 12-month and 720-day
institutional event rates per 100 person-years and calcu-
lated the median of the institutional event rates separately for
each quartile. To examine outcomes up to 365 and 720 days,
we plotted the cumulative incidence using the Kaplan-Meier
method and tested for equality of survivor functions using
the log-rank test.
All statistical analyses were conducted using SAS version
9.2 or higher (SAS Institute Inc., Cary, North Carolina) and
Stata Statistical Software: Release 11 (StataCorp LP,College Station, Texas). All statistical tests were 2 sided,
with a signiﬁcance level of 0.05.
Results
The study population included 247,052 patients who
underwent PCI with stenting between 2005 and 2007 at
656 hospitals (Figs. 1A and 1B). The mean duration of
follow-up was 756 days (25th and 75th percentiles: 512 and
1,047 days). Overall, 79,741 patients (32.3%) underwent
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443stress electrocardiography, stress echocardiography, or stress
nuclear imaging as the ﬁrst test in the interval from 60 to
365 days after coronary stenting, 18,455 (7.5%) underwent
invasive diagnostic coronary angiography as the ﬁrst test, and
148,856 (60.3%) underwent no testing in the 60-day to
365-day interval after coronary stenting.
Institutional quartiles of testing incidence. We examined
the site-level 12-month cumulative incidence rate of stress
testing used as the ﬁrst test within 60 to 365 days after PCI,
with either stress testing or cardiac catheterization used as
the ﬁrst test after PCI. The institutional 12-month cumu-
lative incidence rates of any stress testing varied from 8.6%
to 66.0% (median 31.6%, 25th and 75th percentiles 24.7%
and 38.9%). The intraclass correlation for the cumulative
incidence of noninvasive testing between sites over the study
years was 0.702 (95% conﬁdence interval: 0.668 to 0.735).
Patient and hospital characteristics. After sites were
stratiﬁed into quartiles on the basis of their 12-month
testing cumulative incidence during the study period, we
compared baseline characteristics and demographics of
patients at the time of index PCI. This comparison was done
ﬁrst for quartiles of hospitals on the basis of rates of patients
undergoing stress testing as the ﬁrst test after PCI (Table 1).
STRESS TEST FIRST. Patient characteristics were largely
similar across hospital quartiles for the cumulative incidenceFigure 2 Observed 12-Month Median Outcomes per 100 Person-Yea
Observed 12-month median outcomes per 100 person-years by hospital quartile of stresof testing. Compared with the lowest quartiles of testing
rate, patients undergoing PCI at the highest testing rate
were less likely to be Caucasian and to have a body mass
index 30 kg/m2, previous congestive heart failure, or acute
coronary syndromes at index presentation. There also was
some variability of site characteristics across the quartiles in
the use of drug-eluting stents, annual PCI volumes, and
geography, but there were no clear trends in these differ-
ences across quartiles.
UNADJUSTED OUTCOMES. Clinical outcomes at least 60 days
after index PCI and up to 12 months after index PCI were
examined overall and by hospital testing quartile (Fig. 2).
Overall, the incidence rates of repeat revascularization
(CABG or PCI), AMI, or death within 12 months were
4.1, 2.3, and 5.2, respectively, per 100 person-years.
Adjusted outcomes for patients after PCI. Among
hospital quartiles of stress testing use as the ﬁrst test after
PCI, no statistical difference in the cumulative incidence
of death (p ¼ 0.187) or hospitalization for AMI
(p ¼ 0.51) at 12 months after PCI was found when the
higher 3 quartiles were jointly compared with the lowest
quartile of testing (quartile 1). In contrast, there was
a highly signiﬁcant difference in the incidence of repeat
revascularization at 12 months after PCI (p < 0.001). In
pairwise comparisons, there were statistically signiﬁcantrs by Hospital Quartile
s testing 60 to 365 days after index percutaneous coronary intervention.
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4449% and 20% increases in repeat revascularization among
sites in quartiles 3 and 4, respectively, compared with
Quartile 1 (p ¼ 0.020 and p < 0.001, respectively)
(Fig. 3).
When examining outcomes at least 60 days and up to
720 days after PCI, we found that the cumulative incidence
rate of death for the lowest tested quartile (quartile 1)
compared with the other 3 quartiles was similar, although
statistically signiﬁcant (10.5%, 10.8%, 10.1%, and 10.1%,
respectively, p ¼ 0.011). No signiﬁcant clinical differences
at 720 days were found when comparing quartile 1 with the
other 3 quartiles for the cumulative incidence of hospital-
ization for AMI (4.5%, 4.8%, 4.6%, and 4.3% for quartiles
1 to 4, respectively, p ¼ 0.041). Finally, a signiﬁcant
difference in the rates of repeat revascularization was found
across the 4 groups with increasing rates of revasculariza-
tion as testing quartile increased (13.8%, 13.8%, 14.7%,
and 15.4% for quartiles 1 to 4, respectively, p < 0.001).
When examined by repeat revascularization type (PCI or
CABG), there was no difference in the use of CABG
across the 4 testing quartiles (1.93%, 1.92%, 2.04%, and
1.94% for quartiles 1 to 4, respectively, p ¼ 0.567), whereas
increased for PCI as testing quartile increased (12.3%,Figure 3 Adjusted Outcomes by Noninvasive Testing Quartiles
Adjusted outcomes of noninvasive testing quartiles for death, myocardial infarction (MI),
CI ¼ conﬁdence interval; HR ¼ hazard ratio; PCI ¼ percutaneous coronary intervention.12.3%, 13.2%, and 14.0% for quartiles 1 to 4, respectively,
p < 0.001) at 720 days.
Discussion
In this national cohort of patients undergoing PCI, there
was marked variation in the use of subsequent cardiovascular
testing that is not fully explained by differences in patient
and hospital characteristics. Furthermore, increased use of
testing after PCI is associated with a clear increase in repeat
revascularization; however, the variation of testing and
downstream revascularization did not result in decreased
AMI or mortality.
In the present study, we found signiﬁcant variation in
noninvasive stress testing after PCI across Medicare fee-for-
service sites, with a range of 17% to 73% and a mean of 40%
at 12 months. These rates parallel previous reports of a
cumulative incidence of 36% for either stress echocardiog-
raphy or stress nuclear testing at 12 months in a non-
Medicare population (5). Relative to previous reports in
other PCI analyses, these rates are high, where <15%
patients develop symptoms requiring reevaluation within 12
months after PCI (15,16).and revascularization (Revasc). CABG ¼ coronary artery bypass grafting;
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445In our study, there were no signiﬁcant differences in
patient characteristics among sites stratiﬁed by quartile of
testing use, demonstrating that increased patient risk was
not associated with increased testing use and vice versa.
Speciﬁcally, patient characteristics, such as diabetes or
a history of silent ischemia (i.e., no chest pain before index
PCI) or bare-metal stent use (vs. drug-eluting stent use),
were not more common at sites with more frequent testing.
This ﬁnding is similar to our prior observations in non-
Medicare patients (5), suggesting that signiﬁcant opportu-
nities exist to improve guidance on appropriate indications
for testing.
We used the naturally occurring variation in testing rates
across institutions to explore whether variation in the spec-
iﬁed outcomes might be associated with different testing
intensities. In particular, the variation in testing rates may
be interpreted as a surrogate for the different post-PCI
management strategies of ischemic symptom-driven testing
(lower rates of use) versus surveillance testing (higher rates of
use). The lack of association between stress testing use and
clinical outcomes of death or AMI suggests that the more
intensive testing use (implying a surveillance testing strategy)
did not prevent or reduce post-PCI events in the short to
medium term. This lack of difference in death related to
testing use after PCI parallels ﬁndings from prior studies
examining the association of testing intensity and outcomes
after AMI when controlling for patient characteristics (17).
Nevertheless, our data only imply the presence of different
diagnostic strategies and the associated outcomes.
In contrast to AMI and death, when examining the
physician-guided outcomes of repeat revascularization,
a signiﬁcantly higher utilization (up to 37% more) was found
among sites that tested more frequently after PCI. Addi-
tionally, we found that the use of repeat revascularization
with CABG was constant across testing quartiles, but repeat
PCI increased with increased site testing. This clinical
cascade mirrors previous studies demonstrating that increased
imaging use leads to increased invasive procedures and
interventions (8,9). To our knowledge, our study is the ﬁrst
to use observational data to demonstrate that increased
testing after PCI is not associated with lower rates of death
or AMI, and our ﬁndings are consistent with those of
multiple randomized clinical trials that have found no
reduction in events after PCI (18–20).
Study limitations. Despite the large number of sites and
patient data available, our study had several limitations.
First, data were limited to fee-for-service Medicare and
CathPCI Registry patients. As a result, data on symptoms,
clinical presentation, and ﬁndings at the time of retesting
were unavailable and may differ among groups. It is
unknown if higher rates of testing and revascularization
result in better symptomatic outcomes, which are also
important indicators to patients. Second, we had limited
follow-up for patients and could not observe longer term
(>24 months) outcomes. Despite similar patients across the
utilization quartiles, we could not exclude clinicians whomay have correctly identiﬁed higher clinical risk and may
have acted appropriately on abnormal test results by repeat
coronary intervention. However, given the very low rates of
subsequent repeat revascularization in this population, it is
unlikely that repeat revascularization would be a signiﬁcant
driver of AMI reduction or death in our population. Also,
follow-up events following PCI relied on International
Classiﬁcation of Diseases-Ninth Revision, codes as opposed
to clinically adjudicated events, which could understate the
occurrence of events in our analysis cohort. Finally, we did
not have information regarding other valid reasons to test,
such as patient or provider preferences or need for patient
reassurance.
Conclusions
Our ﬁndings suggest that linking clinically rich patient
registries with administrative data can create a platform to
examine the use of testing after PCI. It is unknown whether
increased testing after PCI with increased subsequent repeat
revascularization is a marker of higher quality post-PCI care
or simply an indication of increased health care utilization.
Future studies should examine the indications for and results
of post-PCI testing to further assess their use for patients to
better understand the associated clinical outcomes.
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APPENDIX
For a list of Current Procedural Terminology and International Classiﬁcation
of Diseases-Ninth Revision-Clinical Modiﬁcation codes, please see the
online version of this article.
